The MCPP challenge test in schizophrenia

Hormonal and behavioral responses

Naveed Iqbal, Gregory M. Asnis, Scott Wetzler, Rene S. Kahn, Stanley R. Kay, Herman M. van Praag

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

In a neuroendocrine challenge paradigm, the present study investigated responses of schizophrenic patients to m-chlorophenylpiperazine (MCPP), a serotonin (5-hydroxytryptamine, 5HT) agonists. In an oral dose of 0.25 mg/kg, MCPP was administered in a placebo-controlled double-blind design to male schizophrenic patients (n = 7) and normal male controls (n = 8). Behavioral (Positive and Negative Syndrome Scale; PANSS) and hormonal (cortisol, prolactin) variables were measured over the subsequent 210 min. The schizophrenic patients experienced an overall exacerbation of psychopathology on MCPP as compared with placebo (p < 0.05), with specific worsening of PANSS-positive symptoms (p < 0.025) and PANSS activation (p < 0.001). In addition, the schizophrenic patients showed significantly lower cortisol (p < 0.05) and prolactin (p < 0.05) responses than the normal subjects. The schizophrenic patients had lower peak MCPP blood levels than the normal subjects, although this difference was not statistically significant. The findings are discussed in terms of 5HT receptor(s) sensitivity and the pharmacokinetics of MCPP in schizophrenia.

Original languageEnglish (US)
Pages (from-to)770-778
Number of pages9
JournalBiological Psychiatry
Volume30
Issue number8
DOIs
StatePublished - Oct 15 1991

Fingerprint

Schizophrenia
Prolactin
Hydrocortisone
Placebos
Serotonin Receptor Agonists
Serotonin Receptors
Psychopathology
Serotonin
Pharmacokinetics
1-(3-chlorophenyl)piperazine

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

The MCPP challenge test in schizophrenia : Hormonal and behavioral responses. / Iqbal, Naveed; Asnis, Gregory M.; Wetzler, Scott; Kahn, Rene S.; Kay, Stanley R.; van Praag, Herman M.

In: Biological Psychiatry, Vol. 30, No. 8, 15.10.1991, p. 770-778.

Research output: Contribution to journalArticle

Iqbal, Naveed ; Asnis, Gregory M. ; Wetzler, Scott ; Kahn, Rene S. ; Kay, Stanley R. ; van Praag, Herman M. / The MCPP challenge test in schizophrenia : Hormonal and behavioral responses. In: Biological Psychiatry. 1991 ; Vol. 30, No. 8. pp. 770-778.
@article{eb29554ab24049bebc2f9aad90eec94b,
title = "The MCPP challenge test in schizophrenia: Hormonal and behavioral responses",
abstract = "In a neuroendocrine challenge paradigm, the present study investigated responses of schizophrenic patients to m-chlorophenylpiperazine (MCPP), a serotonin (5-hydroxytryptamine, 5HT) agonists. In an oral dose of 0.25 mg/kg, MCPP was administered in a placebo-controlled double-blind design to male schizophrenic patients (n = 7) and normal male controls (n = 8). Behavioral (Positive and Negative Syndrome Scale; PANSS) and hormonal (cortisol, prolactin) variables were measured over the subsequent 210 min. The schizophrenic patients experienced an overall exacerbation of psychopathology on MCPP as compared with placebo (p < 0.05), with specific worsening of PANSS-positive symptoms (p < 0.025) and PANSS activation (p < 0.001). In addition, the schizophrenic patients showed significantly lower cortisol (p < 0.05) and prolactin (p < 0.05) responses than the normal subjects. The schizophrenic patients had lower peak MCPP blood levels than the normal subjects, although this difference was not statistically significant. The findings are discussed in terms of 5HT receptor(s) sensitivity and the pharmacokinetics of MCPP in schizophrenia.",
author = "Naveed Iqbal and Asnis, {Gregory M.} and Scott Wetzler and Kahn, {Rene S.} and Kay, {Stanley R.} and {van Praag}, {Herman M.}",
year = "1991",
month = "10",
day = "15",
doi = "10.1016/0006-3223(91)90233-C",
language = "English (US)",
volume = "30",
pages = "770--778",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "8",

}

TY - JOUR

T1 - The MCPP challenge test in schizophrenia

T2 - Hormonal and behavioral responses

AU - Iqbal, Naveed

AU - Asnis, Gregory M.

AU - Wetzler, Scott

AU - Kahn, Rene S.

AU - Kay, Stanley R.

AU - van Praag, Herman M.

PY - 1991/10/15

Y1 - 1991/10/15

N2 - In a neuroendocrine challenge paradigm, the present study investigated responses of schizophrenic patients to m-chlorophenylpiperazine (MCPP), a serotonin (5-hydroxytryptamine, 5HT) agonists. In an oral dose of 0.25 mg/kg, MCPP was administered in a placebo-controlled double-blind design to male schizophrenic patients (n = 7) and normal male controls (n = 8). Behavioral (Positive and Negative Syndrome Scale; PANSS) and hormonal (cortisol, prolactin) variables were measured over the subsequent 210 min. The schizophrenic patients experienced an overall exacerbation of psychopathology on MCPP as compared with placebo (p < 0.05), with specific worsening of PANSS-positive symptoms (p < 0.025) and PANSS activation (p < 0.001). In addition, the schizophrenic patients showed significantly lower cortisol (p < 0.05) and prolactin (p < 0.05) responses than the normal subjects. The schizophrenic patients had lower peak MCPP blood levels than the normal subjects, although this difference was not statistically significant. The findings are discussed in terms of 5HT receptor(s) sensitivity and the pharmacokinetics of MCPP in schizophrenia.

AB - In a neuroendocrine challenge paradigm, the present study investigated responses of schizophrenic patients to m-chlorophenylpiperazine (MCPP), a serotonin (5-hydroxytryptamine, 5HT) agonists. In an oral dose of 0.25 mg/kg, MCPP was administered in a placebo-controlled double-blind design to male schizophrenic patients (n = 7) and normal male controls (n = 8). Behavioral (Positive and Negative Syndrome Scale; PANSS) and hormonal (cortisol, prolactin) variables were measured over the subsequent 210 min. The schizophrenic patients experienced an overall exacerbation of psychopathology on MCPP as compared with placebo (p < 0.05), with specific worsening of PANSS-positive symptoms (p < 0.025) and PANSS activation (p < 0.001). In addition, the schizophrenic patients showed significantly lower cortisol (p < 0.05) and prolactin (p < 0.05) responses than the normal subjects. The schizophrenic patients had lower peak MCPP blood levels than the normal subjects, although this difference was not statistically significant. The findings are discussed in terms of 5HT receptor(s) sensitivity and the pharmacokinetics of MCPP in schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=0026048271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026048271&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(91)90233-C

DO - 10.1016/0006-3223(91)90233-C

M3 - Article

VL - 30

SP - 770

EP - 778

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 8

ER -